A score including ADAM17 substrates correlates to recurring cardiovascular event in subjects with atherosclerosis

Atherosclerosis

Volumn 239, Issue 2, 2015, Pages 459-464

  Stefano, Rizza ^a,b   Massimiliano, Copetti ^c   Marina, Cardellini ^a,b   Rossella, Menghini ^a   Chiara, Pecchioli ^a,b   Alessio, Luzi ^a,b   Giovanni, Di Cola ^a,b   Ottavia, Porzio ^a   Ippoliti, Arnaldo ^a   Franco, Romeo ^a   Fabio, Pellegrini ^c   Massimo, Federici ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^c CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

ADAM17; Atherosclerosis; AVD; Cardiovascular disease outcomes; CEA; CV; Endothelium derived factors; Follow up study; IDI; Inflammation; MACEs; NRI; OGTT; PTCA; RCHD; RECPAM; RIDI; TIMP3

Indexed keywords

CELL ADHESION MOLECULE; INTERLEUKIN 6 RECEPTOR; SOLUBLE INTERCELLULAR CELL ADHESION MOLECULE 1; SOLUBLE INTERLEUKIN 6 RECEPTOR; SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR 1; SOLUBLE VASCULAR CELL ADHESION MOLECULE 1; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; ADAM PROTEIN; BIOLOGICAL MARKER; ICAM1 PROTEIN, HUMAN; IL6R PROTEIN, HUMAN; INTERCELLULAR ADHESION MOLECULE 1; TNFRSF1A PROTEIN, HUMAN; TUMOR NECROSIS FACTOR-ALPHA CONVERTASE;

ACCURACY; ADAM17 SCORE; ADULT; ARTERY SURGERY; ARTICLE; ASSESSMENT OF HUMANS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR PARAMETERS; CORRELATIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SUBSTRATE; FEMALE; FRAMINGHAM RISK SCORE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON FATAL STROKE; ORAL GLUCOSE TOLERANCE TEST; PREDICTION; PRIORITY JOURNAL; RECURRENT DISEASE; TRANSLUMINAL CORONARY ANGIOPLASTY; AGED; BLOOD; CEREBROVASCULAR ACCIDENT; DECISION SUPPORT SYSTEM; ENZYME SPECIFICITY; ENZYMOLOGY; EPIDEMIOLOGY; ITALY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; TIME;

ADAM PROTEINS; ADULT; AGED; ATHEROSCLEROSIS; BIOMARKERS; DECISION SUPPORT TECHNIQUES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, INTERLEUKIN-6; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; ROME; STROKE; SUBSTRATE SPECIFICITY; TIME FACTORS; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84922606218     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.01.029     Document Type: Article

References (31)

1. Glass C.K., Witztum J.L. Atherosclerosis, the road ahead. Cell 2001, 104:503-516.
2. Myers G.L., Christenson R.H., Cushman M., Ballantyne C.M., Cooper G.R., Pfeiffer C.M., Grundy S.M., Labarthe D.R., Levy D., Rifai N., Wilson P.W. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: emerging biomarkers for primary prevention of cardiovascular diseases. Clin. Chem. 2009, 55(2):378-384.
3. Virmani R., Kolodgie F.D., Burke A.P., Farb A., Schwartz S.M. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 2000, 20:1262-1275.
4. Menghini R., Fiorentino L., Casagrande V., Lauro R., Federici M. The role of ADAM17 in metabolic inflammation. Atherosclerosis 2013, 228(1):12-17.
5. Satoh M., Ishikawa Y., Itoh T., Minami Y., Takahashi Y., Nakamura M. The expression of TNF-alpha converting enzyme at the site of ruptured plaques in patients with acute myocardial infarction. Eur. J. Clin. Investig. 2008, 38(2):97-105.
6. Müller A., Krämer S.D., Meletta R., et al. Gene expression levels of matrix metalloproteinases in human atherosclerotic plaques and evaluation of radiolabeled inhibitors as imaging agents for plaque vulnerability. Nucl. Med. Biol. 2011, 41(7):562-569.
7. Cardellini M., Menghini R., Luzi A., Davato F., Cardolini I., D'Alfonso R., Gentileschi P., Rizza S., Marini M.A., Porzio O., Lauro D., Sbraccia P., Lauro R., Federici M. Decreased IRS2 and TIMP3 expression in monocytes from offspring of type 2 diabetic patients is correlated with insulin resistance and increased intima-media thickness. Diabetes 2011, 60(12):3265-3270.
8. Khokha R., Murthy A., Weiss A. Metalloproteinases and their natural inhibitors in inflammation and immunity. Nat. Rev. Immunol. 2013, 13(9):649-665.
9. Rizza S., Copetti M., Cardellini M., Porzio O., Luzi A., Pecchioli C., Martelli E., Valentini A., Ippoliti A., Romeo F., Pellegrini F., Lauro D., Lauro R., Federici M. Atherosclerosis severity but not undiagnosed diabetes predicts new cardiovascular events of subjects in secondary cardiovascular prevention. Atherosclerosis 2012, 223(2):448-453.
10. D'Agostino R.B., Russell M.W., Huse D.M., Ellison R.C., Silbershatz H., Wilson P.W., Hartz S.C. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am. Heart J. 2000, 139(2 Pt 1):272-281.
11. Tahara N., Mukherjee J., de Haas H.J., et al. 2-deoxy-2-[(18)F]fluoro-d-mannose positron emission tomography imaging in atherosclerosis. Nat. Med. 2014, 20(2):215-219.
12. Overall C.M., Blobel C.P. In search of partners: linking extracellular proteases to substrates. Nat. Rev. Mol. Cell Biol. 2007, 8:245-257.
13. Takaguri Akira, Kimura Keita, Hinoki Akinari, Bourne Allison M., Autieri Michael V., Eguchi Satoru Adisintegrin and metalloprotease 17 mediates neointimal hyperplasia in vasculature. Hypertension 2011, 57(4):841-845.
14. Gutwein P., Abdel-Bakky M.S., Schramme A., Doberstein K., Kämpfer-Kolb N., Amann K., Hauser I.A., Obermüller N., Bartel C., Abdel-Aziz A.A., El Sayed el S.M., Pfeilschifter J. CXCL16 is expressed in podocytes and acts as a scavenger receptor for oxidized low-density lipoprotein. Am. J. Pathol. 2009, 174(6):2061-2072.
15. Zhao X.Q., Zhang M.W., Wang F., Zhao Y.X., Li J.J., Wang X.P., Bu P.L., Yang J.M., Liu X.L., Zhang M.X., Gao F., Zhang C., Zhang Y. CRP enhances soluble LOX-1 release from macrophages by activating TNF-α converting enzyme. J.Lipid Res. 2011, 52(5):923-933.
16. Reiss K., Cornelsen I., Husmann M., Gimpl G., Bhakdi S. Unsaturated fatty acids drive disintegrin and metalloproteinase (ADAM)-dependent cell adhesion, proliferation, and migration by modulating membrane fluidity. J.Biol. Chem. 2011, 286(30):26931-26942.
17. Casagrande V., Menghini R., Menini S., et al. Overexpression of tissue inhibitor of metalloproteinase 3 in macrophages reduces atherosclerosis in low-density lipoprotein receptor knockout mice. Arterioscler. Thromb. Vasc. Biol. 2012, 32(1):74-81.
18. Fiorentino L., Vivanti A., Cavalera M., Marzano V., Ronci M., Fabrizi M., Menini S., Pugliese G., Menghini R., Khokha R., Lauro R., Urbani A., Federici M. Increased tumor necrosis factor alpha-converting enzyme activity induces insulin resistance and hepatosteatosis in mice. Hepatology 2010, 51(1):103-110.
19. Stöhr R, Cavalera M, Menini S, Mavilio M, Casagrande V, Rossi C, Urbani A, Cardellini M, Pugliese G, Menghini R, Federici M, Loss of TIMP3 exacerbates atherosclerosis in ApoE null mice, Atherosclerosis 201, 235(2), 438-443.
20. Newby A.C. Proteinases and plaque rupture: unblocking the road to translation. Curr. Opin. Lipidol. 2014, 25(5):358-366.
21. Large-scale gene-centric analysis identiffes novel variants for coronary artery disease. PLoS Genet. 2011, 7:e1002260. The IBC 50K CAD Consortium.
22. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. The Lancet 2012, 379:1214-1224. The Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium.
23. Grundy S.M., Balady G., Criqui M., Fletcher G., Greenland P., Hiratzka L., Houston-Miller N., Kris-Etherton P., Krumholz H., LaRosa J., Ockene I.S., Pearson T.A., Reed J., Washington R., Smith S.C. Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association. Circulation 1998, 97:1876-1887.
24. Greenland P., Knoll M.D., Stamler J., Neaton J.D., Dyer A.R., Garside D.B., Wilson P.W. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 2003, 290:891-897.
25. Khot U.N., Khot M.B., Bajzer C.T., Sapp S.K., Ohman E.M., Brener S.J., Ellis S.G., Lincoff A.M., Topol E.J. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003, 290:898-904.
26. Smith S.C. Current and future directions of cardiovascular risk prediction. Am. J. Cardiol. 2006, 97:28A-32A.
27. Ridker P.M., Buring J.E., Rifai N., Cook N.R. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score. JAMA 2007, 297:611-619.
28. Zethelius B., Berglund L., Sundstrom J., Ingelsson E., Basu S., Larsson A., Venge P., Arnlöv J. Use of multiple biomarkers to improve the prediction of death from cardiovascularcauses. N.Engl. J. Med. 2008, 358:2107-2116.
29. Yousuf O, Mohanty B, Martin S, Joshi PH, Blaha MJ, Nasir K, Blumenthal RS, Budoff MJ, High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link? JACC, 201, 5, 397-408.
30. Naghavi M., Libby P., Falk E., et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part II. Circulation 2003, 108(15):1772-1778. 14.
31. Naghavi M., Libby P., Falk E., et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation 2003, 108(14):1664-1672. 7.